|
|
|
|
| LEADER |
02982nam a22003253i 4500 |
| 001 |
EBC31498760 |
| 003 |
MiAaPQ |
| 005 |
20240729202206.0 |
| 006 |
m o d | |
| 007 |
cr cnu|||||||| |
| 008 |
240729s2020 xx o ||||0 por d |
| 020 |
|
|
|a 9789240004603
|q (electronic bk.)
|
| 035 |
|
|
|a (MiAaPQ)EBC31498760
|
| 035 |
|
|
|a (Au-PeEL)EBL31498760
|
| 040 |
|
|
|a MiAaPQ
|b eng
|e rda
|e pn
|c MiAaPQ
|d MiAaPQ
|
| 245 |
1 |
0 |
|a Elegibilidade Dos Contraceptivos para Mulheres Com Alto Risco de Infecção Pelo HIV. Diretriz :
|b Recomendações Sobre o Uso de Métodos Contraceptivos Por Mulheres Com Alto Risco de Infecção Pelo HIV.
|
| 250 |
|
|
|a 1st ed.
|
| 264 |
|
1 |
|a Geneva :
|b World Health Organization,
|c 2020.
|
| 264 |
|
4 |
|c {copy}2020.
|
| 300 |
|
|
|a 1 online resource (40 pages)
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Intro -- Acknowledgements -- Executive summary -- background -- Methods of guideline review and development -- 2.1 Guideline Development Group -- 2.2 Guideline development process -- 2.3 Evidence Retrieval -- 3.6 Additional evidence considered by the GDG -- 3.6.1 Biological data -- 3.4 Intrauterine devices -- 3.3 Progestogen-only pills -- 3.2 Progestogen-only implants -- 3.1 Progestogen-only injectables -- 2.5 Recommendation formulation -- 2.4 Evidence Synthesis -- 4.2 Rationale -- 4.1 Recommendations for contraceptive use among women at high risk of HIV infection -- 3.6.2 Values and preferences of contraceptive users -- 3.5 Combined hormonal contraceptives -- Implications for policy-makers, programme managers and health-care providers -- 5.1 A woman's risk of HIV should not restrict her contraceptive choice -- 5.2 Efforts to expand access to contraceptive options must continue -- 5.3 A renewed emphasis on HIV and STI prevention services is urgently needed -- 6.1 Contraceptive methods and HIV acquisition -- 6.2 HIV prevention -- 6.4 Increased funding for high-quality, policy-relevant research -- 6.3 Community involvement -- References -- Annex 1. Guideline Development Group and evidence secretariat -- Annex 2. Declarations of conflicts of interest -- Annex 3. GRADE evidence profiles -- Annex 4. Evidence-to- decision table for hormonal contraceptive methods and intrauterine devices (IUDs) -- Annex 5: Systematic reviews.
|
| 588 |
|
|
|a Description based on publisher supplied metadata and other sources.
|
| 590 |
|
|
|a Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
|
| 655 |
|
4 |
|a Electronic books.
|
| 776 |
0 |
8 |
|i Print version:
|t Elegibilidade Dos Contraceptivos para Mulheres Com Alto Risco de Infecção Pelo HIV. Diretriz
|d Geneva : World Health Organization,c2020
|
| 797 |
2 |
|
|a ProQuest (Firm)
|
| 856 |
4 |
0 |
|u https://ebookcentral.proquest.com/lib/matrademy/detail.action?docID=31498760
|z Click to View
|
